Inhibikase Therapeutics, Inc.
NASDAQ:IKT · NASDAQ Capital Market
+$0.06 today
Vol 1.45M · Avg 1.03M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+10.24%
Period High
$2.14
Period Low
$1.41
Latest
$1.83
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$340.24M
Turn Therapeutics Inc.
NASDAQ:TTRX
$173.21M
Surrozen, Inc.
NASDAQ:SRZN
$170.90M
Agenus Inc.
NASDAQ:AGEN
$123.47M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$104.02M
eXoZymes, Inc.
NASDAQ:EXOZ
$65.20M
Entera Bio Ltd.
NASDAQ:ENTX
$59.64M
Estrella Immunopharma, Inc.
ESLA
$43.68M
Tevogen Bio Holdings Inc.
TVGN
$42.83M
Atossa Therapeutics, Inc.
ATOS
$17.14M
What is the latest IKT filing?
The latest filing shown is SC 13G/A dated May 15, 2026.
How many recent filings does IKT have?
Intrinsic Alpha currently shows 20 recent filings for IKT.
Explore More
Continue the stock analysis
Jump to another research area for this company.